The serotonergic system mediates mood, anxiety, sleep, appetite, pain modulation, vasoregulation, and gastrointestinal motility. In neurology, serotonergic pharmacology is central to migraine acute treatment and prophylaxis, depression and anxiety in neurologic patients, neuropathic pain management, and the spectrum of antidepressant and antiemetic drugs. Serotonin pharmacology also produces serotonin syndrome — a potentially fatal toxidrome arising from polypharmacy. This page covers the receptor pharmacology and major drug classes.

Serotonergic Anatomy

  • Raphe nuclei: midline brainstem nuclei (dorsal raphe, median raphe); primary source of CNS serotonin.
  • Wide projections to cortex, limbic system, basal ganglia, cerebellum, spinal cord.
  • Most peripheral serotonin produced by GI enterochromaffin cells.

Serotonin Receptors (5-HT)

Multiple subtypes; most G-protein coupled (except 5-HT3, ligand-gated):

  • 5-HT1A: autoreceptor (presynaptic somatodendritic); also postsynaptic; anxiolytic effects; target of buspirone (partial agonist), some antidepressants.
  • 5-HT1B/D: intracranial vasoconstriction, presynaptic inhibition of CGRP release; target of triptans.
  • 5-HT1F: trigeminal sensory; target of ditans (lasmiditan).
  • 5-HT2A: cortical, smooth muscle; target of atypical antipsychotics (block), pimavanserin (inverse agonist).
  • 5-HT2B: cardiac valves (chronic agonism → valvulopathy); pergolide, cabergoline at high doses.
  • 5-HT2C: cortex, choroid plexus; appetite regulation.
  • 5-HT3: ligand-gated cation channel; chemoreceptor trigger zone (vomiting); target of ondansetron, granisetron.
  • 5-HT4: gastrointestinal motility; target of prucalopride.
  • 5-HT7: circadian rhythms, mood.

Serotonin Synthesis and Metabolism

  • Tryptophan → 5-hydroxytryptophan (tryptophan hydroxylase, rate-limiting) → serotonin (AAAD).
  • Storage: VMAT2.
  • Reuptake: serotonin transporter (SERT).
  • Metabolism: MAO-A (preferentially) → 5-hydroxyindoleacetic acid (5-HIAA, urinary marker).

Major Drug Classes

Selective Serotonin Reuptake Inhibitors (SSRIs)

  • Fluoxetine, sertraline, citalopram, escitalopram, paroxetine, fluvoxamine.
  • Mechanism: block SERT → increase synaptic serotonin.
  • Uses: depression, anxiety, OCD, panic, PTSD; first-line.
  • Neurology uses: depression in stroke, PD, MS, epilepsy patients; functional neurological symptoms; chronic pain; vasovagal syncope prevention; possible benefit in some chronic neurologic conditions.
  • Side effects: GI, sexual dysfunction, insomnia or sedation, weight changes, hyponatremia (SIADH), bleeding risk (platelet function), QT prolongation (citalopram dose limit).
  • Discontinuation syndrome: dizziness, paresthesias, irritability — particularly paroxetine.

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

  • Venlafaxine, desvenlafaxine, duloxetine, milnacipran, levomilnacipran.
  • Block both SERT and NET.
  • Uses: depression, anxiety, neuropathic pain (duloxetine FDA-approved), fibromyalgia (duloxetine, milnacipran), migraine prophylaxis (venlafaxine).
  • Side effects: similar to SSRIs + BP elevation (especially venlafaxine), sweating.

Tricyclic Antidepressants (TCAs)

  • Amitriptyline, nortriptyline, imipramine, desipramine, clomipramine.
  • Mechanism: SERT and NET inhibition (varies by drug); anticholinergic, antihistamine, α1 blockade.
  • Uses in neurology: neuropathic pain (amitriptyline, nortriptyline mainstays), migraine prophylaxis, sleep (low-dose amitriptyline).
  • Side effects: anticholinergic (cognitive, dry mouth, constipation, urinary retention), orthostasis, weight gain, QT prolongation, cardiac conduction (block in overdose), seizure threshold lowering.
  • Overdose: cardiac (sodium channel block — wide QRS), seizures, anticholinergic; serum alkalinization (bicarbonate); restricted prescribing.
  • Nortriptyline often preferred over amitriptyline for lower side-effect burden.

Monoamine Oxidase Inhibitors (MAOIs)

  • Nonselective: phenelzine, isocarboxazid, tranylcypromine.
  • MAO-A selective: moclobemide (reversible; less dietary restriction).
  • MAO-B selective: selegiline (PD; transdermal patch for depression at higher doses, less selective).
  • Mechanism: inhibit MAO breakdown of monoamines → elevated NE, DA, serotonin, tyramine.
  • Uses: treatment-resistant depression, atypical depression.
  • Drug interactions catastrophic: SSRIs (serotonin syndrome), tramadol, meperidine, tyramine-rich foods (hypertensive crisis).
  • Washout: 5 weeks after fluoxetine (long half-life) before MAOI; 2 weeks for other SSRIs.

5-HT Receptor Modulators (Atypical Antidepressants)

  • Mirtazapine: α2 antagonist + 5-HT2/3 antagonist + H1 antagonist; sedating, appetite-stimulating, antiemetic; used in elderly depression with poor appetite.
  • Trazodone: 5-HT2A antagonist + weak SERT inhibitor; sedating; used for insomnia at low doses.
  • Vilazodone: 5-HT1A partial agonist + SERT inhibition.
  • Vortioxetine: 5-HT receptor modulator + SERT; some cognitive benefit data.
  • Nefazodone: 5-HT2A antagonist + SERT; hepatotoxicity → restricted use.
  • Trintellix (vortioxetine): similar to vilazodone class.

Triptans (5-HT1B/1D Agonists)

  • Sumatriptan, rizatriptan, zolmitriptan, eletriptan, almotriptan, naratriptan, frovatriptan.
  • Mechanism: intracranial vasoconstriction + inhibit CGRP release from trigeminal nerves + central pain modulation.
  • Migraine acute treatment.
  • Routes: oral, intranasal, SC (sumatriptan).
  • Contraindications: CAD, uncontrolled HTN, stroke, peripheral vascular disease, basilar/hemiplegic migraine (relative).
  • Side effects: chest tightness, paresthesias, drowsiness.
  • Avoid combining with MAOIs (serotonin syndrome theoretical; clinical rare).
  • Cardiovascular safety questioned but generally safe in low-risk patients.

Ditans (5-HT1F Agonists)

  • Lasmiditan: 5-HT1F selective; no vasoconstriction (safer in CAD).
  • Driving restriction (sedation).

5-HT3 Antagonists (Antiemetics)

  • Ondansetron, granisetron, dolasetron, palonosetron.
  • Block 5-HT3 receptors in chemoreceptor trigger zone.
  • For chemotherapy-induced nausea, postoperative nausea, pregnancy.
  • Safer than dopamine antagonists in PD.
  • QT prolongation risk.

5-HT2A Inverse Agonists

  • Pimavanserin: selective 5-HT2A inverse agonist; no D2 effect.
  • FDA-approved for PD psychosis.
  • QT prolongation.

Buspirone

  • 5-HT1A partial agonist.
  • Generalized anxiety disorder.
  • No sedation, no dependence.
  • Takes weeks for effect.

Serotonergic Migraine Prophylaxis

  • Onabotulinum toxin A: indirectly modulates trigeminal serotonergic transmission.
  • Methysergide: 5-HT2 antagonist; historical; restricted (retroperitoneal fibrosis).
  • Pizotifen: outside US.
  • SSRIs: not effective for migraine prophylaxis (despite anti-depressant use).
  • SNRIs (venlafaxine): migraine prophylaxis.
  • TCAs (amitriptyline): migraine prophylaxis.

Serotonin Syndrome

  • Triad: mental status changes + autonomic hyperactivity + neuromuscular abnormalities (hyperreflexia, clonus, rigidity).
  • Often within 6-24 hours of dose change or addition.
  • Mild: tremor, hyperreflexia, diaphoresis.
  • Severe: hyperthermia (>41°C), severe rigidity, autonomic crisis, death.
  • Triggering combinations: SSRI + tramadol; SSRI + linezolid; SSRI + lithium; SSRI + ondansetron; SSRI + triptan (rare); MAOI + SSRI (severe); MAOI + tyramine.
  • Treatment: discontinue all serotonergic drugs, cyproheptadine, benzodiazepines for agitation, aggressive cooling, ICU care.
  • Hunter criteria: clinical diagnosis.

🔍 Did You Know?

Serotonin syndrome from polypharmacy is one of the most dangerous and underrecognized adverse drug events in modern medicine, particularly in neurology and oncology where patients are exposed to multiple serotonergic agents. The classic combinations — MAOI + SSRI, MAOI + meperidine — are now rare because of clinical awareness, but newer at-risk combinations are surprisingly common: SSRI + tramadol (the leading cause of serotonin syndrome in many recent series), SSRI + linezolid (the antibiotic linezolid is a reversible MAOI), SSRI + lithium, SSRI + ondansetron, and SSRI + methylene blue (used in parathyroidectomy and as a tracer). Tramadol-SSRI combination is particularly insidious because tramadol is so widely prescribed for pain that even experienced clinicians may not check for SSRI interactions. The clinical presentation can range from mild tremor and hyperreflexia (often missed or attributed to other causes) to fatal autonomic crisis with severe hyperthermia. Diagnostic criteria (Hunter’s) emphasize spontaneous clonus or inducible clonus + agitation + sweating as a high-sensitivity triad. The lesson generalizes: polypharmacy in modern medicine has created a new pharmacology — the pharmacology of drug-drug interactions, and every prescription requires the cognitive step of asking “what else is this patient on?” The American Society of Anesthesiologists, oncology societies, and pharmacology references all now emphasize specific medication review before procedures involving methylene blue or before adding antiemetics in serotonergic-burdened patients.

Pitfalls and Pearls

  • 5-HT1A: autoreceptor and anxiolytic; buspirone partial agonist.
  • 5-HT1B/D: triptan target; intracranial vasoconstriction + anti-CGRP.
  • 5-HT1F: ditan target (lasmiditan); no vasoconstriction.
  • 5-HT2A: atypical antipsychotic target (block); pimavanserin inverse agonist for PD psychosis.
  • 5-HT3: chemoreceptor trigger zone; ondansetron blocks.
  • SSRIs: depression, anxiety; first-line; bleeding risk; hyponatremia in elderly.
  • SNRIs: depression + neuropathic pain (duloxetine), migraine prophylaxis (venlafaxine).
  • TCAs: neuropathic pain (amitriptyline, nortriptyline), migraine prophylaxis; nortriptyline less anticholinergic.
  • Triptans: acute migraine; avoid in CAD, uncontrolled HTN, stroke, basilar/hemiplegic migraine.
  • Ditans (lasmiditan): alternative when triptans contraindicated by CV.
  • Anti-CGRP gepants (rimegepant, ubrogepant): acute + prophylactic migraine; no vasoconstriction.
  • Serotonin syndrome: SSRI + tramadol/linezolid/lithium/ondansetron/MAOI.
  • Hunter criteria: clonus + agitation + sweating triad.
  • Treatment of serotonin syndrome: discontinuation + cyproheptadine + benzos + cooling.
  • MAOI washout: 5 weeks after fluoxetine, 2 weeks others.
  • Pimavanserin: 5-HT2A inverse agonist; PD psychosis without motor worsening.

References

  1. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill; 2023.
  2. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.
  3. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria. QJM. 2003;96(9):635-642.
  4. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000;55(6):754-762.
  5. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622.
  6. Stahl SM. Stahl’s Essential Psychopharmacology. 5th ed. Cambridge University Press; 2021.